[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopausal-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopausal-symptoms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,85,125,153,182,203,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100641801","meleis-transition-theory-based-education-and-counseling-program-in-menopausal-women-100641801",false,"NCT07657078","Meleis' Transition Theory-Based Education and Counseling Program in Menopausal Women","The Effect of a Meleis' Transition Theory-Based Education and Counseling Program on Menopausal Symptoms, Perimenopausal Depression, and Menopause-Specific Quality of Life in Menopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female participants aged 45 to 55 years\n* Naturally menopausal women\n* Menopause duration not exceeding 2 years\n* Experiencing menopausal symptoms\n* Sexually active\n* Able to read and write Turkish\n* Willing to participate voluntarily\n* Able to provide written informed consent\n* Not currently receiving hormone replacement therapy\n* No history of psychiatric disorders\n* No previous menopause-related education\n\nExclusion Criteria:\n\n* Failure to continue participation in the study\n* Failure to attend education and counseling sessions\n* Withdrawal from the study at any time\n* Withdrawal of informed consent\n* Loss to follow-up","FEMALE","45 Years","55 Years",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to evaluate the effectiveness of a Meleis' Transition Theory-based education and counseling program on menopausal symptoms, perimenopausal depression, and menopause-specific quality of life among naturally menopausal women aged 45 to 55 years.\n\nParticipants will be randomly assigned to either the intervention group or the control group. The intervention group will receive a structured four-week education and counseling program based on Meleis' Transition Theory, supported by a secure online messaging group and follow-up counseling sessions. The control group will receive routine care and standard information during the study period and will be offered a one-day educational session after completion of the final assessment.\n\nThe outcomes will be measured at baseline and Week 16 using the Menopause Rating Scale, the Perimenopausal Depression Scale, and the Menopause-Specific Quality of Life Questionnaire-II.",[27,28,29],"Menopause","Menopausal Symptoms","Perimenopausal Depression",[27,31,32,33,34,35,36,37,38,39],"Menopausal transition","Meleis' Transition Theory","Education","Counseling","Menopausal symptoms","Perimenopausal depression","Quality of life","Women's health","Nursing","NOT_YET_RECRUITING","2026-06-17",{"date":43,"type":44},"2026-06-22","ACTUAL",{"date":46,"type":21},"2026-06-15",{"date":48,"type":21},"2026-10-15",{"name":50,"class":51},"Ankara Medipol University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":52},"100640580","structured-combined-exercise-program-in-postmenopausal-women-effects-on-heart-rate-variability-and-menopausal-symptoms-100640580","NCT07615790","Structured Combined Exercise Program in Postmenopausal Women: Effects on Heart Rate Variability and Menopausal Symptoms","The Effect of a Structured Combined Exercise Program on Heart Rate Variability and Menopausal Symptoms in Postmenopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women in the postmenopausal period\n* Aged between 45 and 65 years\n* Able to communicate and cooperate with the researchers\n* Not participating in another structured exercise program\n* Willing to participate voluntarily in the study\n\nExclusion Criteria:\n\n* Presence of severe cardiovascular, neurological, orthopedic, or psychiatric disease\n* Hormone replacement therapy use during the study period\n* Cognitive impairment affecting participation\n* Uncontrolled hypertension or other unstable medical conditions\n* Regular participation in structured exercise training within the last 6 months\n* Smoking or alcohol use that may affect heart rate variability measurements","65 Years",{"count":62,"type":21},40,[24],"The goal of this clinical trial is to learn whether a structured combined exercise program can improve heart health, menopausal symptoms, sleep quality, and quality of life in postmenopausal women aged 45 to 65 years.\n\nThe main questions it aims to answer are:\n\nDoes the exercise program improve heart rate variability, which shows how well the heart is controlled by the nervous system? Does the exercise program lower menopausal symptoms? Does the exercise program improve sleep quality and quality of life?\n\nResearchers will compare women who join the exercise program with women who continue their usual daily activities.\n\nParticipants in the exercise group will take part in a supervised exercise program for 12 weeks. They will exercise 2 days each week. Each session will last 45 minutes and will include warm-up, balance, strengthening, coordination, flexibility, and cool-down exercises.\n\nParticipants in the control group will continue their usual daily activities during the study.",[66,28,67,68],"Postmenopausal","Autonomic Nervous System Diseases","Sleep Wake Disorders",[70,71,72,73,35,74,37],"Structured combined exercise","Postmenopausal women","Heart rate variability","Cardiac autonomic function","Sleep quality","RECRUITING","2026-05-28",{"date":78,"type":44},"2026-05-29",{"date":80,"type":44},"2026-04-27",{"date":82,"type":21},"2026-09",{"name":84,"class":51},"Fenerbahce University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100639808","prevalence-of-menopause-associated-symptoms-throughout-the-menopausal-transition-in-women-aged-40-to-70-residing-in-spain-and-its-relationship-with-physical-activity---mdh-study-100639808","NCT07596069","Prevalence of Menopause-associated Symptoms Throughout the Menopausal Transition in Women Aged 40 to 70 Residing in Spain and Its Relationship With Physical Activity - MdH Study","Prevalence of Menopause-associated Symptoms Throughout the Menopausal Transition in Women Aged 40 to 70 Residing in Spain and Its Relationship With Physical Activity.","Inclusion Criteria:\n\n* Female sex.\n* Age 40 to 70 years.\n* Residence in Spain.\n* Ability to understand and complete the online questionnaire.\n\nExclusion Criteria:\n\n* Residence outside Spain.\n* Age below 40 years or above 70 years.\n* Difficulty understanding the study information or questionnaire.",true,"40 Years","70 Years",{"count":96,"type":21},15000,"OBSERVATIONAL","The goal of this observational study is to learn about menopause-related symptoms in women aged 40 to 70 years who live in Spain. The study will also look at whether physical activity, body weight, health history, social factors, and risk of osteoporotic fracture are linked to these symptoms.\n\nMenopause-related symptoms can affect daily life, sleep, mood, sexual health, and physical well-being. These symptoms may be different depending on whether a woman is in premenopause, perimenopause, or postmenopause. This study aims to better understand these symptoms in women living in Spain and to explore whether women who are more physically active report fewer or less bothersome symptoms.\n\nThe main questions this study aims to answer are:\n\nHow common are menopause-related symptoms in women aged 40 to 70 years who live in Spain? Do symptoms differ between women in premenopause, perimenopause, and postmenopause? Are women with higher levels of physical activity less likely to report bothersome menopause-related symptoms? Are body weight, age, health history, social factors, or osteoporotic fracture risk linked to more bothersome symptoms? Can the study identify groups of women who may be more likely to have a higher symptom burden?\n\nParticipants will complete an online survey one time. The survey will take about 15 to 25 minutes. Participants will answer questions about:\n\nAge, place of residence, education, work situation, and other personal information Weight and height Menstrual history and reproductive history Current menopause stage Health history and current treatments Tobacco and alcohol use Type, amount, and setting of physical activity Time spent sitting Menopause-related symptoms during the last month Factors related to osteoporotic fracture risk, such as previous fractures, family history of hip fracture, smoking, alcohol use, use of corticosteroids, rheumatoid arthritis, and other health conditions\n\nThe survey will include three standard questionnaires. The Menopause-Specific Quality of Life Questionnaire will ask about symptoms in four areas: hot flashes and sweating, mood and social well-being, physical symptoms, and sexual health. The International Physical Activity Questionnaire will ask about physical activity during the last 7 days, including activity at work, transport, household tasks, leisure time, and time spent sitting. The Fracture Risk Assessment Tool will estimate the risk of osteoporotic fracture using clinical risk factors.\n\nThis is an observational study. Researchers will not assign participants to any treatment, exercise program, or medical care. The study will collect information through online questionnaires and will analyze links between menopause-related symptoms, physical activity, fracture risk, and other participant characteristics.",[28,100],"Physical Activity and Sedentary Behavior",[28,102,27,103,38,104,105,106,107,108,109,110,111,112,113],"Women Reproductive Stages","Perimenopause","Spanish Women","Physical activity","Menopause transition","Vasomotor symptoms","Mood symptoms","Osteoporotic fracture risk","IPAQ","MENQOL","FRAX","Exercise habits","2026-05-12",{"date":116,"type":44},"2026-05-19",{"date":118,"type":44},"2026-04-18",{"date":120,"type":21},"2026-12",{"name":122,"class":123},"Cuerpos Serranos S.L.","INDUSTRY",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":18,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":52},"100604420","effect-of-mandala-practice-on-menopausal-symptoms-and-quality-of-life-100604420","NCT07149285","Effect of Mandala Practice on Menopausal Symptoms and Quality of Life","Inclusion Criteria:\n\n1. The study included women who met the following conditions:\n2. Absence of cognitive, hearing, or speech impairments that could interfere with effective communication,\n3. No physical, psychological, or visual limitations that could hinder participation in mandala coloring activities,\n4. Literacy in Turkish, including the ability to read, comprehend, and write,\n5. A confirmed medical diagnosis of menopause,\n6. Not undergoing any form of psychotherapy or alternative treatment throughout the study period,\n7. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Participants were excluded from the study if they:\n2. Provided incomplete or inaccurate responses in the data collection forms,\n3. Were receiving hormone therapy to manage menopausal symptoms,\n4. Had a neurological disorder that could impair concentration or communication during the mandala activity,\n5. Had known allergies to paints or similar substances.",{"count":132,"type":21},78,[24],"Menopause is a natural cycle of life that mostly develops due to changes in the endocrine glands of the female body during middle age, and the menstrual cycle is permanently interrupted as a result of the ovaries losing their activity. Many symptoms are observed in women during menopause, and these symptoms cause women to experience many physiological, mental, social and sexual problems in the short or long term and to deteriorate their quality of life. In reducing the menopause symptoms experienced by women, hormone replacement therapy, traditional methods, mental or physical applications; aromatherapy, hypnosis, Biofeedback and relaxation techniques are used. The aim of these applications; is to relax women, reduce menopausal symptoms and increase their quality of life. Mandala, which has been widely used in the field of therapy in the past and today, is seen as a meditation tool in art therapy and is defined as a complementary, safe and accessible activity that supports mental health. It has been determined that how the mandala method, which is used in many areas in the literature, affects the symptoms and quality of life of women in the menopausal period has not been examined. For this reason, it is thought that this study will make a significant contribution to the literature.",[136,137,28],"Menopause Symptom Management","Quality of Life",[139,140,141,142,143],"menopause","mandala painting","menopausal symptoms","quality of life","nursing","2025-08-27",{"date":146,"type":44},"2025-08-29",{"date":148,"type":21},"2025-09",{"date":150,"type":21},"2025-10",{"name":152,"class":51},"Emine Karacan",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":52},"100595625","effects-of-mindfulness-based-self-efficacy-development-program-on-postmenopausal-women-100595625","NCT07034885","Effects of Mindfulness-Based Self-Efficacy Development Program on Postmenopausal Women","Effects of Mindfulness-Based Self-Efficacy Development Program on Menopausal Symptoms and Quality of Life in Postmenopausal Women: A Randomized Controlled Trial","MOPKA","Inclusion Criteria:\n\nInclusion criteria:\n\n* Individuals who are in the +1a or +1b substage of early postmenopause according to the STRAW+10 system (at least 12 months and at most 24 months have passed since their last menstrual period)\n* Are proficient in reading and writing Turkish\n* Are in a spouse or partner\n* Have entered menopause naturally\n* Do not have a physical disability such as a severe musculoskeletal disorder, neurological disease, or mobility limitation that would prevent the use of mindfulness techniques (e.g., seated meditation, breathing exercises, gentle body awareness exercises)\n* Have not used MBSR techniques in the last six months\n* Own a smartphone or internet-enabled device.\n\nExclusion Criteria:\n\n* Those who completed the pretest data collection forms incompletely,\n* Those who had any psychological disorder or experienced a traumatic event in the last two to one years,\n* Those who received hormone replacement therapy during menopause,\n* Those who had any gynecological cancer","57 Years",{"count":163,"type":21},70,[24],"The aim of this randomized controlled clinical trial is to evaluate the effects of a mindfulness-based self-efficacy development program on menopausal symptoms and quality of life in postmenopausal women. The main questions it aims to answer are:\n\nDoes the mindfulness-based program reduce the severity of menopausal symptoms?\n\nDoes the mindfulness-based program improve the quality of life of postmenopausal women?\n\nDoes the mindfulness-based program significantly increase participants' overall self-efficacy?\n\nThe researchers will compare whether there are differences between the mindfulness-based training program applied to the intervention group and the control group in terms of menopausal symptoms, quality of life, and self-efficacy scores.\n\nThe main tasks that will be asked of the participants are as follows:\n\nThose in the intervention group will participate in a face-to-face mindfulness-based self-efficacy development program, each session lasting at least 120 minutes, once a week for 8 weeks, with a maximum of 10 people per group.\n\nThe control group will not receive any intervention.\n\nParticipants in both groups will be evaluated with a personal information form and measurement tools such as the Menopause Symptoms Assessment Scale, the Menopause Specific Quality of Life Scale, and the General Self-efficacy Scale.",[167,28,137,168,169],"Postmenopausal Period","Stress Management","Self-Efficacy",[27,169,137,171],"Mindfulness","2025-07-17",{"date":174,"type":44},"2025-07-22",{"date":176,"type":21},"2025-09-15",{"date":178,"type":21},"2026-02-28",{"name":180,"class":181},"Nurcan Gökgöz","OTHER_GOV",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":92,"sex":16,"minAge":18,"maxAge":60,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100585198","efficacy-of-cl22205-on-bone-mineral-density-and-menopausal-symptoms-100585198","NCT06899243","Efficacy of CL22205 on Bone Mineral Density and Menopausal Symptoms","The Effect of CL22205 on Bone Mineral Density and Menopausal Symptoms in Women: A Randomized, Double-blind, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Healthy females aged between 55 and 65 years with a Body mass index (BMI) of approximately 24 and 29 kg\u002Fm2.\n* Women with menopausal symptoms (modified Kupperman index scores 15-29), absence of menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) \\> 30 mIU\u002FmL; estradiol \\\u003C 30 pg\u002FmL.\n* Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) and calcium carbonate.\n* Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA).\n* Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes.\n* Subject understands the study procedures and provides signed informed consent to participate in the study.\n* Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical biochemistry, haematology, lipid profile, thyroid profile and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.\n\nExclusion Criteria:\n\n* Consumption of functional food or supplement that modifies body composition, during or 6 months prior to the study.\n* History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years.\n* Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.\n* Presence of chronic diseases that prevent the performance of a physical exercise program (disabling arthropathies, moderate \u002F severe chronic lung disease, arrhythmias, etc.).\n* High alcohol intake (\\>2 standard drinks per day), or recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.\n* Smokers or tobacco users.\n* Inability to understand informed consent.\n* Serious or terminal illnesses.\n* Fasting blood glucose level \\>125 mg\u002Fdl.\n* Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.\n* Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months.\n* Taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).\n* Active gall bladder disease, gynaecological (including hysterectomy) or breast surgery in the last 6 months.\n* Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.\n* Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.\n* History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.\n* History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.\n* History of positive hepatitis screening including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and \u002For syphilis.\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.\n* Participated in a clinical study with an investigational drug or biologic within the last 30 days.\n* Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.",{"count":190,"type":21},80,[24],"The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.",[28],"2025-03-21",{"date":196,"type":44},"2025-03-27",{"date":198,"type":21},"2025-03-25",{"date":200,"type":21},"2026-08-30",{"name":202,"class":123},"Eetho Brands, Inc",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":52},"100484337","phase-3-micronized-progesterone-versus-norethisterone-acetate-in-combination-with-estrogen-as-menopausal-hormone-therapy-100484337","NCT05586724","Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy","Safety of Oral Micronized Progesterone Versus Norethisterone Acetate in Continuous Combination With Oral Estrogen as Menopausal Hormone Therapy - a Double-blind Randomized Study- PROBES Study (Progesterone Breast Endometrial Safety Study)","Inclusion Criteria:\n\n* Healthy and naturally postmenopausal women (more than one year since last menstruation or FSH \\> 40 IE\u002FL) with climacteric symptoms (sweating, hot flush and\u002For sleep problems) that adversely affect the quality of life\n* Age 45-60 years\n* BMI \\> 19 kg\u002Fm2 and ≤ 32 kg\u002Fm2\n* Intact uterus\n* In case of previous MHT use, washout 8 weeks for oral MHT and 4 weeks for transdermal MHT or local estrogen treatment before screening\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous history or risk factors for breast cancer, breast cancer in situ or abnormal mammogram at baseline as assessed clinically by a radiology expert\n* Previous history or risk factors for endometrial cancer or hyperplasia or abnormal\u002Fproliferative endometrial biopsy at baseline\n* Vaginal bleeding\n* Any concomitant medical treatment except for well-controlled hypertension, non-insulin treated type 2 diabetes, asthma and hypothyroidism\n* History or presence of or risk factor for cardiovascular disease including thromboembolic disorder or cerebrovascular disease\n* History or presence of liver and gallbladder disease, familial hyperlipidemia, epilepsy or classical migraine with aura\n* History or presence of clinically significant depression or other psychiatric disorder that might in anyway compromise the performance of the trial or undermine its scientific validity\n* Porphyria, Systemic lupus erythematosus and otosclerosis\n* Current use of MHT or local estrogen treatment\n* Alcohol and\u002For drug abuse\n* Clinically significant findings on physical and\u002For gynecological examination at baseline\n* Hypersensitivity to any of the study treatments","60 Years",{"count":212,"type":21},520,[214],"PHASE3","About one third of all women during menopausal transition have significant climacteric symptoms with considerable impact on quality of life. Meta-analysis has shown a beneficial risk profile with menopausal hormone therapy (MHT) for women 50 to 60 years. Still, there is a great need to find safe MHT able to control excessive endometrial stimulation by estrogen without stimulatory effects on the breast by the combination of estrogen\u002Fprogestogen. Recent observational studies indicate a lower risk for breast cancer using micronized progesterone (mP) combined with estrogen but increased risk of endometrial cancer than by standard MHT. In a randomized trial, the balance between benefits and risks of mP vs. progestogens (norethisterone (NETA)) in combination with estrogen will be explored. For apparent reasons, long-term largescale clinical trials with endometrial and breast cancer as the primary endpoints, are not feasible. However, much knowledge can be obtained using relevant surrogate markers. Mammographic breast density is a strong risk factor for breast cancer, and endometrial hyperplasia is a strong risk factor for endometrial cancer. The primary objective is to compare the effects of one year treatment with mP versus progestogen, in combination with estradiol on mammographic breast density. Furthermore, to evaluate the effect of one year treatment with mP in continuous combination with estradiol on endometrial pathology (hyperplasia and cancer).",[28],[218,219,220,221,222,223],"Menopausal hormone therapy","Climacteric symptoms","Progesterone","Progestogens","Breast safety","Endometrial safety","2024-06-02",{"date":226,"type":44},"2024-06-04",{"date":228,"type":44},"2022-03-15",{"date":230,"type":21},"2027-12",{"name":232,"class":51},"Angelica Lindén Hirschberg",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":92,"sex":16,"minAge":240,"maxAge":18,"enrollmentInfo":241,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":52},"100527689","an-observational-study-of-menopausal-symptom-in-patients-with-gynecological-malignancy-after-oophorectomy-100527689","NCT06151028","An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy","An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy (Carnation1)","Inclusion Criteria:\n\n* Premenopausal women with gynecological malignancies aged 18-55 years old;\n\n  * Tumor types include endometrial cancer, cervical cancer, epithelial ovarian cancer;\n\n    * All patients received standard stage operation and treatment;\n\n      * Patients with bilateral ovaries resection; ⑤Voluntarily participate in this study, willing to sign informed consent, and have long-term follow-up conditions.\n\nExclusion Criteria:\n\n* Menopause (women over 40 years of age stop menstruation for 12 months, excluding pregnancy and other diseases that may cause amenorrhea can be clinically diagnosed as menopause); Or AMH \\\u003C 0.2ng\u002Fml (China Menopause Management and Menopause Hormone Therapy Guidelines 2023 edition); Or FSH\\> 40 mIU\u002Fml after two checks within one month;\n\n  * Other tumors were combined within 2 years and were still in radiotherapy, chemotherapy or hormone therapy;\n\n    * Diagnosis of immunodeficiency disease or active hepatitis B, C, active tuberculosis; ④Serious organic diseases of the organs, etc., can not cooperate with the study follow-up; ⑤Long-term use of hormonal drugs for rheumatic system diseases, such as glucocorticoids;\n\n      * Patients who have previously received pelvic or abdominal radiotherapy; ⑦ ECOG score ≥3 points; ⑧The patient did not sign informed consent or was unwilling to accept follow-up interviews.","18 Years",{"count":242,"type":21},490,"Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.",[245,28,246],"Gynecological Malignancies","Bone Loss","2024-03-06",{"date":249,"type":44},"2024-03-07",{"date":251,"type":44},"2023-12-01",{"date":253,"type":21},"2033-12-31",{"name":255,"class":181},"Anhui Provincial Hospital"]